Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.

Inclusion Criteria: * Age ≥18 years * Diagnosis of type 2 diabetes mellitus * Urinary albumin-to-creatinine ratio \>20 mg/g (2.26 mg/mmol) * eGFR \>30 ml/min/1.73m2 * Willing to sign informed consent Exclusion Criteria: * Diagnosis of type 1 diabetes * Prior treatment with SGLT2 inhibitor in the four weeks prior to randomization * History of severe hypersensitivity or contraindications to dapagliflozin * Unable to monitor blood pressure / body weight or handle digital technologies * History of non-adherence to medical regimens or unwillingness to comply with the study protocol * Participation in any clinical investigation within 3 months prior to initial dosing * Unstable or rapidly progressing renal disease * Severe hepatic impairment (Child-Pugh class C) as determined by the treating physician. * Active malignancy * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: History of active inflammatory bowel disease, within the last six months; Major gastrointestinal tract surgery as decided by the treating physician; Pancreatitis within the last six months; Evidence of serious hepatic disease as determined by the treating physician; Evidence of urinary obstruction or difficulty in voiding at screening. * Confirmed lactose intolerance demonstrated with a lactose intolerance test. * Donation or loss of 400 mL of blood within 8 week…